TSHA Taysha Gene Therapies Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TSHA

Price (delayed)

$2.57

Market cap

$480.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.96

Enterprise value

$393.56M

Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to ...

Highlights
Taysha Gene Therapies's quick ratio has surged by 177% YoY
Taysha Gene Therapies's EPS has surged by 75% YoY and by 63% QoQ
The debt has grown by 3.1% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://tayshagtx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of TSHA
Market
Shares outstanding
187.02M
Market cap
$480.64M
Enterprise value
$393.56M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.41
Price to sales (P/S)
19.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.47
Earnings
Revenue
$15.45M
EBIT
-$106.57M
EBITDA
-$104.02M
Free cash flow
-$76.89M
Per share
EPS
-$0.96
Free cash flow per share
-$0.66
Book value per share
$0.4
Revenue per share
$0.13
TBVPS
$1.49
Balance sheet
Total assets
$172.73M
Total liabilities
$97.79M
Debt
$59.46M
Equity
$74.94M
Working capital
$113.11M
Liquidity
Debt to equity
0.79
Current ratio
4.08
Quick ratio
3.99
Net debt/EBITDA
0.84
Margins
EBITDA margin
-673.2%
Gross margin
100%
Net margin
-722.1%
Operating margin
-468.8%
Efficiency
Return on assets
-80.9%
Return on equity
N/A
Return on invested capital
-1,211.6%
Return on capital employed
-78.4%
Return on sales
-689.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TSHA stock price

How has the Taysha Gene Therapies stock price performed over time
Intraday
-0.39%
1 week
7.53%
1 month
-5.51%
1 year
280.8%
YTD
45.2%
QTD
-10.45%

Financial performance

How have Taysha Gene Therapies's revenue and profit performed over time
Revenue
$15.45M
Gross profit
$15.45M
Operating income
-$72.44M
Net income
-$111.57M
Gross margin
100%
Net margin
-722.1%
TSHA's operating margin has soared by 93% YoY and by 39% QoQ
The net margin has soared by 89% YoY and by 52% from the previous quarter
The operating income has surged by 55% year-on-year and by 34% since the previous quarter
Taysha Gene Therapies's net income has increased by 48% QoQ and by 33% YoY

Growth

What is Taysha Gene Therapies's growth rate over time

Valuation

What is Taysha Gene Therapies stock price valuation
P/E
N/A
P/B
6.41
P/S
19.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.47
Taysha Gene Therapies's EPS has surged by 75% YoY and by 63% QoQ
TSHA's price to sales (P/S) is 47% more than its last 4 quarters average of 13.1
Taysha Gene Therapies's revenue has increased by 8% QoQ

Efficiency

How efficient is Taysha Gene Therapies business performance
Taysha Gene Therapies's return on sales has surged by 89% YoY and by 53% QoQ
The return on invested capital has surged by 74% since the previous quarter
Taysha Gene Therapies's return on assets has surged by 52% QoQ and by 33% YoY

Dividends

What is TSHA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TSHA.

Financial health

How did Taysha Gene Therapies financials performed over time
The company's total assets is 77% higher than its total liabilities
Taysha Gene Therapies's quick ratio has surged by 177% YoY
The current ratio has soared by 165% year-on-year
The debt is 21% less than the equity
Taysha Gene Therapies's debt to equity has surged by 168% QoQ but it has shrunk by 99% YoY
The debt has grown by 3.1% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.